{
    "Trade/Device Name(s)": [
        "SeptiCyte RAPID"
    ],
    "Submitter Information": "Immunexpress, Inc.",
    "510(k) Number": "K203748",
    "Predicate Device Reference 510(k) Number(s)": [
        "K163260"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PRE"
    ],
    "Summary Letter Date": "December 21, 2020",
    "Summary Letter Received Date": "December 23, 2020",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3215"
    ],
    "Regulation Name(s)": [
        "Rt-Qpcr Assay For Mrna Transcript Immune Biomarkers"
    ],
    "Analyte Class(es)": [
        "genetic molecular",
        "immunology",
        "microbiology"
    ],
    "Analyte(s)": [
        "PLA2G7",
        "PLAC8"
    ],
    "Specimen Type(s)": [
        "Whole blood"
    ],
    "Specimen Container(s)": [
        "PAXgene Blood RNA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Biocartis Idylla System"
    ],
    "Method(s)/Technology(ies)": [
        "Reverse transcription quantitative PCR (RT-qPCR)",
        "Gene expression assay",
        "Fluorescence detection"
    ],
    "Methodologies": [
        "Gene expression profiling",
        "RT-PCR",
        "Molecular expression testing"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay",
        "Cartridge",
        "System",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Immunexpress SeptiCyte RAPID gene expression assay using RT-qPCR on Biocartis Idylla System to aid differentiation of sepsis from non-infectious inflammation.",
    "Indications for Use Summary": "Used in conjunction with clinical assessment to aid in differentiating infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis on first day of ICU admission, via gene expression analysis from whole blood collected in PAXgene Blood RNA tube.",
    "fda_folder": "Microbiology"
}